Want to see HK:2158 full AI Analyst Report?
Top Page
Yidu Tech, Inc.
(2158)
Select Model
Select Model
Rating:52Neutral
Price Target:
HK$4.00
▼(-28.32% Downside)
Action:Reiterated
Date:08/25/26
The score is driven primarily by improving financial performance in 2026 and a low-debt balance sheet, which reduces solvency risk. However, the overall rating is held back by weak technical momentum (downtrend across key moving averages with negative MACD) and a high P/E valuation that requires more consistent operating profitability and cash-flow stability.
Positive Factors
Low Leverage
Very low leverage limits refinancing and solvency risk, preserving financial flexibility for continued investment in healthcare data and AI platforms while reducing the likelihood that debt obligations constrain operations during periods of uneven profitability.
Negative Factors
Negative Core Operating Profit
Positive net income is not yet supported by sustained operating earnings power. Continued negative operating profit and EBITDA suggest the core business may still lack sufficient scale, pricing strength, or cost discipline to produce durable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low leverage limits refinancing and solvency risk, preserving financial flexibility for continued investment in healthcare data and AI platforms while reducing the likelihood that debt obligations constrain operations during periods of uneven profitability.
Read all positive factors
Yidu Tech, Inc. (2158) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$4.23B
Dividend Yield1.01%
Average Volume (3M)6.36M
Price to Earnings (P/E)51.6
Beta (1Y)1.73
Revenue Growth16.87%
EPS GrowthN/A
CountryHK
Employees754
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.07
Shares Outstanding1,072,892,200
10 Day Avg. Volume7,880,599
30 Day Avg. Volume6,357,449
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)1.25
Price to Sales (P/S)5.73
P/FCF Ratio-87.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.80Price Target Upside21.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.05
Revenue Forecast (FY)HK$972.31M
Yidu Tech, Inc. Business Overview & Revenue Model
Company Description
Yidu Tech Inc. is a technology company that develops and deploys healthcare solutions leveraging big data and artificial intelligence. Its operations extend across Mainland China, Brunei, and other global regions. The company's business activities...
How the Company Makes Money
Yidu Tech makes money primarily by selling technology-enabled services and software/platform solutions to customers in the pharmaceutical/life-sciences sector and the healthcare provider sector. Its revenue model generally includes: (1) solutions ...
Yidu Tech, Inc. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
78
Positive
Cash Flow
52
Neutral
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 790.51M | 714.98M | 807.08M | 804.70M | 1.24B |
| Gross Profit | 288.01M | 239.18M | 339.44M | 274.50M | 396.89M |
| EBITDA | -54.86M | -89.62M | -170.77M | -579.98M | -715.70M |
| Net Income | 70.15M | -117.79M | -194.94M | -627.97M | -762.32M |
Balance Sheet | |||||
| Total Assets | 4.30B | 4.69B | 4.82B | 4.91B | 4.72B |
| Cash, Cash Equivalents and Short-Term Investments | 2.22B | 3.30B | 3.70B | 3.75B | 3.77B |
| Total Debt | 71.09M | 129.54M | 95.20M | 14.13M | 52.16M |
| Total Liabilities | 612.04M | 711.37M | 732.21M | 755.36M | 715.34M |
| Stockholders Equity | 3.63B | 3.92B | 4.02B | 4.08B | 3.99B |
Cash Flow | |||||
| Free Cash Flow | -51.63M | -350.78M | -367.20M | -374.60M | -672.14M |
| Operating Cash Flow | -22.00M | -248.81M | -326.38M | -357.01M | -614.68M |
| Investing Cash Flow | -257.82M | 116.71M | 466.90M | -2.34B | 3.39B |
| Financing Cash Flow | -363.06M | 20.04M | 82.21M | 361.45M | -35.23M |
Yidu Tech, Inc. Technical Analysis
Negative
5.58
Price Trends
4.49
Negative
5.01
Negative
5.25
Negative
Market Momentum
-0.21
Positive
42.18
Neutral
28.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2158, the sentiment is Negative. The current price of 5.58 is above the 20-day moving average (MA) of 4.11, above the 50-day MA of 4.49, and above the 200-day MA of 5.25, indicating a bearish trend. The MACD of -0.21 indicates Positive momentum. The RSI at 42.18 is Neutral, neither overbought nor oversold. The STOCH value of 28.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2158.
Yidu Tech, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$5.22B | 13.10 | 7.00% | 4.12% | 6.47% | 8.10% | |
57 Neutral | HK$14.13B | 25.38 | 4.62% | 160.60% | 7.92% | 152.75% | |
52 Neutral | HK$4.23B | 51.57 | 1.88% | 1.01% | 16.87% | ― | |
52 Neutral | HK$984.05M | -19.74 | -1.56% | 10.05% | 7.95% | 60.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$778.74M | -44.60 | -5.98% | ― | -3.77% | 73.89% |
* Healthcare Sector Average
HK:2158
Yidu Tech, Inc.
3.97
-2.16
-35.27%
HK:1833
Ping An Healthcare and Technology Company
6.54
-14.68
-69.20%
HK:9960
Kindstar Globalgene Technology, Inc.
0.95
-0.42
-30.72%
HK:2192
Medlive Technology Co., Ltd.
7.05
-6.60
-48.35%
HK:9686
NEUSOFT XIKANG HOLDINGS INC.
0.93
-0.09
-9.31%
HK:2506
Xunfei Healthcare Technology Co., Ltd.
71.10
-37.70
-34.65%
Yidu Tech, Inc. Corporate Events
Yidu Tech Unit Wins RMB8.6 Million Hospital IT Infrastructure Contract
Aug 10, 2026
Yidu Tech Inc. has announced that its affiliate Yidu Cloud (Beijing) Technology Co., Ltd. has won the bid to build the IT infrastructure for the Tongzhou campus of Capital Children’s Medical Center, affiliated with Capital Medical University...
Yidu Tech Sets AGM to Approve Dividend, Board Mandates and Share-Issuance Authority
Jul 24, 2026
Yidu Tech Inc. has convened its annual general meeting for August 28, 2026 in Beijing, where shareholders will review and adopt the audited consolidated financial statements for the year ended March 31, 2026 and vote on a proposed final dividend. ...
Yidu Tech Turns Profitable as Medical AI Business Accelerates
Jun 29, 2026
Yidu Tech reported that the global medical AI sector is entering a new phase of technological maturity, with large models, multimodal data and real-world clinical integration driving demand for comprehensive AI solutions. The company has built a f...
Yidu Tech Declares Final Cash Dividend for FY2026
Jun 29, 2026
Yidu Tech Inc. has declared a final ordinary cash dividend of HKD 0.04 per share for the financial year ended 31 March 2026, with payment scheduled for 16 September 2026 following shareholder approval on 28 August 2026. The ex-dividend date is set...
Yidu Tech Delays FY2026 Results and Postpones Board Meeting
Jun 28, 2026
Yidu Tech has delayed the publication of its audited annual results for the year ended March 31, 2026, after its audit committee received information from a third party about the conduct of an employee. With the help of an independent forensic exp...
Yidu Tech Delays Board Meeting to Finalize Annual Results
Jun 22, 2026
Yidu Tech Inc. has postponed its scheduled board meeting, originally set for June 22, 2026, to June 28, 2026, to allow additional time to finalize its audited consolidated annual results for the year ended March 31, 2026. The rescheduled meeting w...
Yidu Tech Schedules Board Meeting to Approve Annual Results and Consider Final Dividend
Jun 9, 2026
Yidu Tech Inc. has scheduled a board meeting for June 22, 2026 to review and approve the audited consolidated annual results for the year ended March 31, 2026. The board will also consider the publication of these results and the potential declara...
Yidu Tech Plans RMB400 Million Acquisition of Online Doctors’ Platform
Jun 1, 2026
Yidu Tech has signed a non-legally binding memorandum of understanding to acquire 100% of a company operating an online doctors’ platform and related services for about RMB400 million, subject to due diligence and definitive agreements. The ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.